RS63523B1 - Novi glp-1 analozi - Google Patents

Novi glp-1 analozi

Info

Publication number
RS63523B1
RS63523B1 RS20220814A RSP20220814A RS63523B1 RS 63523 B1 RS63523 B1 RS 63523B1 RS 20220814 A RS20220814 A RS 20220814A RS P20220814 A RSP20220814 A RS P20220814A RS 63523 B1 RS63523 B1 RS 63523B1
Authority
RS
Serbia
Prior art keywords
analogues
novel glp
glp
novel
Prior art date
Application number
RS20220814A
Other languages
English (en)
Inventor
Rajamannar Thennati
Nishith Chaturvedi
Vinod Sampatrao Burade
Pradeep Dinesh Shahi
Muthukumaran Natarajan
Ravishankara Madavati Nagaraja
Rishit Mansukhlal Zalawadia
Kunal Pandya
Brijeshkumar Patel
Dhiren Rameshchandra Joshi
Krunal Harishbhai Soni
Abhishek Tiwari
Vipulkumar Shankarbhai Patel
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of RS63523B1 publication Critical patent/RS63523B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transmission And Conversion Of Sensor Element Output (AREA)
RS20220814A 2018-04-05 2019-04-05 Novi glp-1 analozi RS63523B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201821013109 2018-04-05
IN201821040468 2018-10-26
IN201821040474 2018-10-26
EP19724915.4A EP3774862B1 (en) 2018-04-05 2019-04-05 Novel glp-1 analogues
PCT/IB2019/052835 WO2019193576A1 (en) 2018-04-05 2019-04-05 Novel glp-1 analogues

Publications (1)

Publication Number Publication Date
RS63523B1 true RS63523B1 (sr) 2022-09-30

Family

ID=66589592

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20240706A RS65639B1 (sr) 2018-04-05 2019-04-05 Novi glp-1 analozi
RS20220814A RS63523B1 (sr) 2018-04-05 2019-04-05 Novi glp-1 analozi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20240706A RS65639B1 (sr) 2018-04-05 2019-04-05 Novi glp-1 analozi

Country Status (30)

Country Link
US (6) US11447535B2 (sr)
EP (3) EP4122954B1 (sr)
JP (2) JP7250814B2 (sr)
KR (1) KR20200141469A (sr)
CN (2) CN117964735A (sr)
AU (2) AU2019247936C1 (sr)
BR (1) BR112020020419A2 (sr)
CA (1) CA3095988A1 (sr)
CL (1) CL2020002574A1 (sr)
CO (1) CO2020012425A2 (sr)
DK (2) DK3774862T3 (sr)
EC (1) ECSP20070185A (sr)
ES (1) ES2925678T3 (sr)
FI (1) FI4122954T3 (sr)
HR (1) HRP20221054T1 (sr)
HU (1) HUE060135T2 (sr)
IL (1) IL277483A (sr)
JO (1) JOP20200251A1 (sr)
LT (2) LT4122954T (sr)
MX (1) MX2020010505A (sr)
PE (1) PE20211417A1 (sr)
PH (1) PH12020551591A1 (sr)
PL (2) PL4122954T3 (sr)
PT (2) PT3774862T (sr)
RS (2) RS65639B1 (sr)
SG (1) SG11202009467YA (sr)
SI (2) SI3774862T1 (sr)
UA (1) UA128210C2 (sr)
WO (1) WO2019193576A1 (sr)
ZA (1) ZA202306729B (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4122954B1 (en) * 2018-04-05 2024-04-03 Sun Pharmaceutical Industries Limited Novel glp-1 analogues
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
EP4204440A1 (en) * 2020-10-17 2023-07-05 Sun Pharmaceutical Industries Limited Glp-1/gip dual agonists
CN114685646B (zh) * 2020-12-31 2023-04-07 厦门赛诺邦格生物科技股份有限公司 一种多肽侧链类似物的制备方法及其应用
KR102691149B1 (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CN116514952B (zh) * 2022-10-13 2024-02-02 江苏师范大学 一类glp-1类似物及其应用
CN117756914A (zh) * 2023-12-15 2024-03-26 瀚晖制药有限公司 依柯胰岛素的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
RU2214419C2 (ru) 1996-08-30 2003-10-20 Ново Нордиск А/С Glp-1 производные
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
AU2610599A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
DE69942307D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PL202367B1 (pl) 1998-12-07 2009-06-30 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje zawierające te związki oraz zastosowanie tych związków
ATE424413T1 (de) 2000-06-16 2009-03-15 Lilly Co Eli Analoge des glucagon-ähnlichen peptids-1
KR20080085082A (ko) 2000-12-07 2008-09-22 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 융합 단백질
CA2468700A1 (en) 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
CA2502118A1 (en) 2002-10-11 2004-05-06 Sanwa Kagaku Kenkyusho Co., Ltd. Glp-1 derivatives and transmicosal absorption preparations thereof
WO2004078777A2 (en) 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Dipeptidyl-peptidase protected proteins
US7259234B2 (en) 2003-05-15 2007-08-21 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
SI2932981T1 (sl) 2003-09-19 2021-11-30 Novo Nordisk A/S Albumin-vezavni derivati GLP-1
EP2210900A3 (en) 2003-12-16 2010-08-11 Ipsen Pharma Analogues of GLP-1
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
AU2006224537A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended GLP-1 compounds
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2006121860A2 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
US8318668B2 (en) 2005-09-08 2012-11-27 Trustees Of Tufts College Stabilized GLP-1 analogs
ES2397289T3 (es) 2005-09-22 2013-03-06 Biocompatibles Uk Ltd. Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
EP2190460B1 (en) 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
ES2558155T3 (es) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
US20120329711A1 (en) 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
EP2565205B1 (en) 2010-04-27 2015-07-01 Betta Pharmaceuticals Co., Ltd. Glucagon-like peptide-1 analogue and use thereof
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
US9006178B2 (en) 2010-11-09 2015-04-14 Novo Nordisk A/S Double-acylated GLP-1 derivatives with a linker
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
WO2013037690A1 (en) 2011-09-06 2013-03-21 Novo Nordisk A/S Glp-1 derivatives
EP2578599A1 (en) 2011-10-07 2013-04-10 LanthioPep B.V. Cyclic analogs of GLP-1 and GLP-1 related peptides
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
CN104411322B (zh) 2012-05-08 2017-05-24 诺和诺德股份有限公司 双酰化glp‑1衍生物
SG11201407860PA (en) 2012-06-14 2014-12-30 Sanofi Sa Exendin-4 peptide analogues
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
AU2013360721A1 (en) 2012-12-21 2015-07-09 Sanofi Exendin-4 Derivatives as dual GLP1/GIP or trigonal GLP1/GIP/Glucagon Agonists
MX2015016564A (es) 2013-06-20 2016-04-15 Novo Nordisk As Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos.
WO2014209886A1 (en) 2013-06-23 2014-12-31 Wisconsin Alumni Research Foundation Alpha/beta-polypeptide analogs of glucagon-like peptid-1
CN105377884B (zh) 2013-07-04 2021-07-20 诺和诺德股份有限公司 Glp-1样肽的衍生物和其用途
US10266577B2 (en) 2013-08-15 2019-04-23 Novo Nordisk A/S GLP-1 derivatives, and uses thereof
AR098065A1 (es) * 2013-10-17 2016-04-27 Zealand Pharma As Análogos de glucagón acilados
EP3080155A1 (en) 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
JP2017502003A (ja) 2013-12-13 2017-01-19 メディミューン リミテッド プロテアーゼ耐性ペプチド
US11572398B2 (en) 2014-11-27 2023-02-07 Novo Nordisk A/S GLP-1 derivatives and uses thereof
JP6691125B2 (ja) 2014-12-17 2020-04-28 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
US10111932B2 (en) 2015-08-26 2018-10-30 Syracuse University Coagonists of glucagon-like peptide 1 receptor and neuropeptide Y2 receptor
US10946074B2 (en) 2016-03-03 2021-03-16 Novo Nordisk A/S GLP-1 derivatives and uses thereof
KR20190017017A (ko) 2016-06-09 2019-02-19 메디뮨 리미티드 프로테아제-내성 모노-지질화된 펩타이드
WO2018083335A1 (en) 2016-11-07 2018-05-11 Novo Nordisk A/S Dchbs-active esters of peg compounds and their use
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
WO2018178796A1 (en) * 2017-03-27 2018-10-04 Sun Pharmaceutical Industries Limited Method for making kex1 protease sensitive polypeptides using yeast strain
WO2019170918A1 (en) 2018-03-09 2019-09-12 Enzypep B.V. Chemo-enzymatic synthesis of liraglutide, semaglutide and glp-1
EP4122954B1 (en) * 2018-04-05 2024-04-03 Sun Pharmaceutical Industries Limited Novel glp-1 analogues

Also Published As

Publication number Publication date
CA3095988A1 (en) 2019-10-10
EP4364751A2 (en) 2024-05-08
SI3774862T1 (sl) 2022-10-28
RS65639B1 (sr) 2024-07-31
MX2020010505A (es) 2021-01-15
WO2019193576A1 (en) 2019-10-10
PH12020551591A1 (en) 2021-08-16
SI4122954T1 (sl) 2024-07-31
FI4122954T3 (fi) 2024-06-18
JP7250814B2 (ja) 2023-04-03
LT4122954T (lt) 2024-06-25
JOP20200251A1 (ar) 2020-10-04
BR112020020419A2 (pt) 2021-01-19
EP4122954B1 (en) 2024-04-03
EP4364751A3 (en) 2024-06-26
AU2019247936C1 (en) 2023-06-15
KR20200141469A (ko) 2020-12-18
JP2023078367A (ja) 2023-06-06
US20220402991A1 (en) 2022-12-22
EP3774862A1 (en) 2021-02-17
HUE060135T2 (hu) 2023-02-28
LT3774862T (lt) 2022-09-12
PT4122954T (pt) 2024-06-05
IL277483A (en) 2020-11-30
EP3774862B1 (en) 2022-06-08
US20210206823A1 (en) 2021-07-08
US11866477B2 (en) 2024-01-09
US20220402992A1 (en) 2022-12-22
CN112236444A (zh) 2021-01-15
PT3774862T (pt) 2022-09-05
JP2021520346A (ja) 2021-08-19
ECSP20070185A (es) 2021-01-29
US11485766B2 (en) 2022-11-01
ZA202306729B (en) 2024-03-27
CN117964735A (zh) 2024-05-03
US11242373B2 (en) 2022-02-08
AU2019247936A1 (en) 2020-10-15
CO2020012425A2 (es) 2020-12-21
UA128210C2 (uk) 2024-05-08
DK3774862T3 (da) 2022-09-05
EP4122954A1 (en) 2023-01-25
CL2020002574A1 (es) 2021-06-04
AU2023203430A1 (en) 2023-06-29
PL3774862T3 (pl) 2022-10-03
US20200362007A1 (en) 2020-11-19
ES2925678T3 (es) 2022-10-19
SG11202009467YA (en) 2020-10-29
US11873328B2 (en) 2024-01-16
DK4122954T3 (da) 2024-06-10
US20240199718A1 (en) 2024-06-20
US11447535B2 (en) 2022-09-20
PE20211417A1 (es) 2021-08-02
HRP20221054T1 (hr) 2022-11-11
US20190309040A1 (en) 2019-10-10
AU2019247936B2 (en) 2023-03-02
PL4122954T3 (pl) 2024-08-12

Similar Documents

Publication Publication Date Title
IL277483A (en) New anti-GLP-1 analogs
CA190078S (en) Case
GB202005105D0 (en) n
GB2582783B (en) Checkpointing
IL283385A (en) Different analogs of gip peptide
GB2577682B (en) Auto-injector
PL3630806T3 (pl) Analogi peptydów gip o długotrwałym działaniu
GB2589548B (en) Auto-Injector
GB2575149B (en) Lanyards
GB201800400D0 (en) Structural components
EP3906225C0 (en) PANTOTHENAMIDE ANALOGUES
ZA202100322B (en) Polytunnel structure
GB2591977B (en) Auto-Injector
GB202002530D0 (en) N
CA204449S (en) Auto-injector
CA189431S (en) Case
CA189432S (en) Case
GB2576916B (en) Polytunnel structure
GB202006585D0 (en) n
GB2575634B (en) Polytunnel structure
GB201908550D0 (en) n
GB201818676D0 (en) Polytunnel structure
GB201803158D0 (en) Improved structure